Page 99 - MI-2-2

Microbes & Immunity Big data and DNN-based DTI model in CHP

Figure 6. Training loss and validation loss of the deep neural network-based drug-target interaction model (five-fold cross-validation)

Figure 7. Training accuracy and validation accuracy of the deep neural network-based drug-target interaction model (five-fold cross-validation)

low toxicity, and high sensitivity, to identify potential 3.2. The roles of mitogen-activated protein kinase
molecular drugs for CHP treatment. and phosphoinositide 3-kinase signaling pathways
The investigation of core signaling pathways of CHP in CHP pathogenesis
and non-CHP, along with their downstream target genes From the core signaling pathways of CHP in Figure 4, the
and cellular dysfunctions to uncover the pathogenetic
mechanisms of CHP, in which significant biomarkers were MAPK signaling cascade emerges as a central regulatory
identified as drug targets for the treatment of CHP is given node in the pathogenesis of CHP, orchestrating inflammatory
in the following subsections. responses, oxidative stress, apoptosis, and fibrosis. Our

Volume 2 Issue 2 (2025) 91 doi: 10.36922/mi.4620